Background: Cyclic vomiting syndrome (CVS) is defined by its episodic patterning. Furthermore, CVS is associated with other episodic disorders such as migraine and epilepsy. Indeed, many of the medications that are known to be useful for prophylaxis and abortive therapy in CVS are also effective in preventing and aborting migraines and seizures. These observations strongly suggest that CVS has a neural basis, but the precise pathophysiological mechanisms that operate in CVS remain unclear.
Purpose: This brief review describes recent neurophysiological insights and opportunities to further advance the understanding of pathophysiological neural mechanisms that are present in patients with CVS. These insights are poised to translate into the next generation of neurotherapeutic strategies for CVS using central neuromodulation. Additionally, the development of neurophysiological tests of neural excitability could be positioned to shape management decisions in future CVS care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/nmo.14991 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of Single Nucleotide Polymorphisms in Cysteamine Dioxygenase Gene with Taurine Content in Oyster Crassostrea gigas.
Mar Biotechnol (NY)
January 2025
Liaoning Key Laboratory of Marine Animal Immunology, Dalian Ocean University, Dalian, 116023, China.
The Pacific oyster Crassostrea gigas is rich in taurine, a conditionally essential amino acid functioning in anti-oxidation, anti-inflammation, anti-aging, osmoregulation, and neuromodulation. Breeding oyster varieties with enhanced taurine content is significant to meet people's demand for high-quality oysters. In the present study, polymorphisms in the oyster cysteamine dioxygenase (CgADO) gene that encodes the central enzyme of the cysteamine pathway for taurine synthesis were investigated, and their association with taurine content was assessed in the Changhai (CH) and Qinhuangdao (QHD) populations.
View Article and Find Full Text PDFBasic Science and Pathogenesis.
Alzheimers Dement
December 2024
Sapienza University of Rome, Rome, Italy.
Background: Huntington's disease (HD) is a progressive neurodegenerative disorder phenotypically manifested by motor, cognitive and psychiatric symptoms (Novak and Tabrizi, 2011). These patients are also characterized by vigilance abnormalities. This has been demonstrated by electrophysiological measures (Wiegand et al.
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
Research Program on Cognition & Neuromodulation Based Interventions, Ann Arbor, MI, USA.
Background: The multisite SuperAging Research Initiative (SRI) was established in 2021 to identify resilience and resistance factors promoting cognitive healthspan through a harmonized multidisciplinary protocol with prospective data collection. The designation of SuperAger is reserved for individuals age 80+ with episodic memory performance that is at least average for those 2-3 decades younger. Research studies of this relatively uncommon phenotype allow for investigations of fundamental importance to the neurobiology of brain aging, resilience, resistance, and avoidance of cognitive decline related to "average aging" and more severe impairments associated with Alzheimer's and related dementias (ADRD).
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
University of Toronto, Toronto, ON, Canada.
Background: Apathy in Alzheimer's disease (AD) is associated with cognitive impairment, particularly executive functions such as selective attention, making it unclear whether apathy should be a separate treatment target. Apathy in Dementia Methylphenidate Trial 2 (ADMET 2) is the largest and most recent trial assessing apathy and cognition. This analysis assessed whether changes in apathy correlated to changes in various cognitive domains in ADMET 2.
View Article and Find Full Text PDFWTAP/IGF2BP3 Mediated m6A Modification of SOD2 mRNA Aggravates the Tumourigenesis of Colorectal Cancer.
J Biochem Mol Toxicol
January 2025
Department of Gastrointestinal Surgery, Zibo Central Hospital, Zibo, China.
Wilms tumor 1-associated protein (WTAP) has been validated to be a crucial regulator in the tumorigenesis and advancement of diverse malignancies. This study intended to probe the impacts of WTAP on colorectal cancer (CRC) progression from the perspective of N6-methyladenosine (m6A) modification. The differential expression patterns of WTAP in clinical CRC samples and cultured cell lines were validated via qRT-PCR and western blot.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!